PT Hartadinata Abadi Tbk (IDX:HRTA)
Indonesia · Delayed Price · Currency is IDR 650.00
+25.00 (4.00%)
Aug 1, 2025, 4:13 PM WIB
SpringWorks Therapeutics Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 25,038,564 | 18,228,629 | 12,857,029 | 6,918,454 | 5,237,905 | 4,138,627 | Upgrade | |
Revenue Growth (YoY) | 67.78% | 41.78% | 85.84% | 32.08% | 26.56% | 27.91% | Upgrade |
Cost of Revenue | 23,716,437 | 17,134,009 | 11,912,414 | 6,178,148 | 4,668,143 | 3,717,985 | Upgrade |
Gross Profit | 1,322,128 | 1,094,620 | 944,615 | 740,305 | 569,763 | 420,641 | Upgrade |
Selling, General & Admin | 232,210 | 218,882 | 236,958 | 192,208 | 144,037 | 65,150 | Upgrade |
Operating Expenses | 232,210 | 218,882 | 236,958 | 192,208 | 144,037 | 65,150 | Upgrade |
Operating Income | 1,089,918 | 875,738 | 707,657 | 548,098 | 425,725 | 355,492 | Upgrade |
Interest Expense | -309,416 | -289,278 | -267,703 | -222,715 | -175,148 | -142,041 | Upgrade |
Interest & Investment Income | 3,249 | 2,682 | 2,319 | 2,217 | 819.36 | 3,757 | Upgrade |
Currency Exchange Gain (Loss) | -2,342 | -2,816 | -8,000 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -30,521 | -19,470 | -38,117 | -1,416 | -3,231 | 997.86 | Upgrade |
EBT Excluding Unusual Items | 750,889 | 566,856 | 396,156 | 326,183 | 248,165 | 218,205 | Upgrade |
Gain (Loss) on Sale of Assets | 226.82 | 226.82 | 2.03 | - | - | - | Upgrade |
Pretax Income | 751,116 | 567,083 | 396,158 | 326,183 | 248,165 | 218,205 | Upgrade |
Income Tax Expense | 165,290 | 124,363 | 89,889 | 72,056 | 53,733 | 47,120 | Upgrade |
Earnings From Continuing Operations | 585,826 | 442,720 | 306,269 | 254,128 | 194,432 | 171,085 | Upgrade |
Minority Interest in Earnings | -764.02 | -539.28 | -463.68 | -606.57 | -456.28 | 86.16 | Upgrade |
Net Income | 585,062 | 442,181 | 305,805 | 253,521 | 193,976 | 171,171 | Upgrade |
Net Income to Common | 585,062 | 442,181 | 305,805 | 253,521 | 193,976 | 171,171 | Upgrade |
Net Income Growth | 79.52% | 44.60% | 20.62% | 30.70% | 13.32% | 14.03% | Upgrade |
Shares Outstanding (Basic) | 4,605 | 4,605 | 4,605 | 4,605 | 4,605 | 4,605 | Upgrade |
Shares Outstanding (Diluted) | 4,605 | 4,605 | 4,605 | 4,605 | 4,605 | 4,605 | Upgrade |
EPS (Basic) | 127.04 | 96.02 | 66.40 | 55.05 | 42.12 | 37.17 | Upgrade |
EPS (Diluted) | 127.04 | 96.02 | 66.40 | 55.05 | 42.12 | 37.17 | Upgrade |
EPS Growth | 79.52% | 44.60% | 20.62% | 30.70% | 13.32% | 14.03% | Upgrade |
Free Cash Flow | -996,544 | -612,188 | -450,380 | -47,620 | -420,803 | -697,235 | Upgrade |
Free Cash Flow Per Share | -216.39 | -132.93 | -97.80 | -10.34 | -91.37 | -151.40 | Upgrade |
Dividend Per Share | 21.000 | 21.000 | 15.000 | 12.000 | 10.000 | 8.000 | Upgrade |
Dividend Growth | 40.00% | 40.00% | 25.00% | 20.00% | 25.00% | - | Upgrade |
Gross Margin | 5.28% | 6.00% | 7.35% | 10.70% | 10.88% | 10.16% | Upgrade |
Operating Margin | 4.35% | 4.80% | 5.50% | 7.92% | 8.13% | 8.59% | Upgrade |
Profit Margin | 2.34% | 2.43% | 2.38% | 3.66% | 3.70% | 4.14% | Upgrade |
Free Cash Flow Margin | -3.98% | -3.36% | -3.50% | -0.69% | -8.03% | -16.85% | Upgrade |
EBITDA | 1,117,165 | 899,342 | 727,103 | 562,703 | 438,795 | 367,460 | Upgrade |
EBITDA Margin | 4.46% | 4.93% | 5.66% | 8.13% | 8.38% | 8.88% | Upgrade |
D&A For EBITDA | 27,247 | 23,604 | 19,446 | 14,605 | 13,069 | 11,968 | Upgrade |
EBIT | 1,089,918 | 875,738 | 707,657 | 548,098 | 425,725 | 355,492 | Upgrade |
EBIT Margin | 4.35% | 4.80% | 5.50% | 7.92% | 8.13% | 8.59% | Upgrade |
Effective Tax Rate | 22.01% | 21.93% | 22.69% | 22.09% | 21.65% | 21.59% | Upgrade |
Advertising Expenses | - | 3,470 | 11,160 | 16,893 | 4,237 | 4,065 | Upgrade |
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.